Pancuronium Pediatric Dose — Neuromuscular Blockade
Pancuronium is a non-depolarizing aminosteroid neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction, producing skeletal muscle paralysis. It is used in pediatric patients to facilitate endotracheal intubation and provide sustained neuromuscular blockade during mechanical ventilation or surgical procedures. Its relatively long duration of action distinguishes it from shorter-acting agents in the paralytic class.
Pediatric Dosing
- Dose: 0.1 mg/kg IV per dose
- Duration of action: 30–60 minutes
- Contraindication: Avoid in renal failure (pancuronium and its active metabolites are renally cleared; accumulation may lead to prolonged blockade)
For a 20 kg child: 20 × 0.1 mg/kg = 2 mg IV per dose. For a 10 kg child: 10 × 0.1 mg/kg = 1 mg IV per dose. Consult institutional protocol for repeat dosing intervals and maximum cumulative dose guidance.
Indications and Clinical Context
Pancuronium is indicated as a non-depolarizing neuromuscular blocking agent for facilitation of endotracheal intubation and maintenance of neuromuscular blockade in mechanically ventilated pediatric patients. It may be considered when a longer duration of paralysis is clinically desirable, such as in PICU settings requiring sustained ventilator synchrony or during prolonged procedures. Its use should be part of a comprehensive sedation and analgesia plan, as neuromuscular blocking agents provide no analgesia or sedation.
Because of its extended duration (30–60 minutes) relative to agents such as vecuronium or rocuronium at standard doses, pancuronium is generally selected when sustained blockade is preferred over rapid reversibility. Clinicians should weigh this against the drug’s vagolytic properties, which may cause tachycardia.
Administration and Monitoring
Pancuronium is administered exclusively by the intravenous (IV) route. Ensure adequate sedation and analgesia are established prior to administration, as paralysis without analgesia or sedation is inappropriate. Monitor for cardiovascular effects, particularly tachycardia and hypertension, which result from the drug’s vagolytic and sympathomimetic properties.
- Route: IV only
- Administer as a slow IV bolus
- Monitor neuromuscular function using train-of-four stimulation when appropriate in the PICU setting
- Avoid in renal failure — active metabolites accumulate and may cause unpredictably prolonged blockade
- Have reversal agents (neostigmine with atropine or glycopyrrolate) and airway rescue equipment immediately available
- Consult institutional protocol for dosing in neonates and patients with hepatic impairment
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.